XBiotech Inc

4XB

Company Profile

  • Business description

    XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

  • Contact

    5217 Winnebago Lane
    AustinTX78744
    USA

    T: +1 512 386-2900

    E: [email protected]

    http://www.xbiotech.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    87

Stocks News & Analysis

stocks

ASX energy share undervalued ahead of earnings

Pricing strength outweighs temporary production headwinds.
stocks

Tesla: Reported China divestiture plan could clear path for SpaceX merger

Media report says Tesla is exploring divestiture plans to ease regulatory approval of a Tesla-SpaceX merger.
stocks

This onetime AI market darling is now surprisingly undervalued

This AI leader qualifies as a GARP stock today.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,130.9022.200.24%
CAC 408,509.6424.000.28%
DAX 4025,629.2417.210.07%
Dow JONES (US)52,485.03276.970.53%
FTSE 10010,868.0529.22-0.27%
HKSE25,884.4325.550.10%
NASDAQ25,373.85251.681.00%
Nikkei 22563,076.131,285.89-2.00%
NZX 50 Index13,716.5717.290.13%
S&P 5007,489.7252.090.70%
S&P/ASX 2008,971.1022.100.25%
SSE Composite Index3,832.2627.570.72%

Market Movers